Tiespectus

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameTiespectus
Drug Alias NameEYE201EYE-201MK-8748
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTEK receptor tyrosine kinase agonistsVascular endothelial growth factor inhibitors
TargetsTEK receptor tyrosine kinaseVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEyebiotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIngenia Therapeutics IncEyebiotech Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaChoroidal NeovascularizationRetinal Vein Occlusion +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A